
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Aceso Life Science Holding
Deal Size : Undisclosed
Deal Type : Agreement
Details : The Joint Venture Company is vested with the exclusive right to develop, register, distribute and commercialize Promethera®'s therapeutic products (cell therapies and antibodies developed by Promethera® Group) in China and Southeast Asia.
Product Name : HepaStem
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 17, 2020
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Aceso Life Science Holding
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial is open for recruitment and aims to include 363 patients with ACLF at 110 study sites across 22 countries in Europe.
Product Name : HepaStem
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 08, 2020
Lead Product(s) : Heterologous Human Adult Liver Derived Progenitor Cell,HepaStem
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
